Trials / Completed
CompletedNCT04310111
EUS-RFA for Unresectable Pancreatic Cancer
Efficacy and Safety of Endoscopic Ultrasonography-guided Radiofrequency Ablation in Treatment of Locally Advanced, Unresectable Pancreatic Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- First People's Hospital of Hangzhou · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events. The aim of this study was to evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. Patients with unresectable PDAC who underwent EUS-RFA were included from September 2013 to June 2016. Pre- and post-procedural clinical data was retrospective collected.
Detailed description
evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | EUS-RFA | Use EUS-RFA to treat unresectable pancreatic cancer |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2021-07-25
- Completion
- 2021-08-25
- First posted
- 2020-03-17
- Last updated
- 2021-08-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04310111. Inclusion in this directory is not an endorsement.